Retatrutide Price from Supplier Brand Shenzhen Zhaoke Biotechnology Co., Ltd. on Chemsrc.com

Published date: 2026-05-27 00:21:29

CAS number: 2381089-83-2

Price:
$432.12/10mg $6847.04/1g

Purity: 98.77%

Stocking period: 3 Day

Stock: In Stock

Product Webpage: http://www.zhaokebio.com

Detail Product Information:
Retatrutide (development code LY3437943) is a first-in-class triple hormone receptor agonist peptide developed by Eli Lilly and Company, designed for the treatment of obesity and type 2 diabetes. It simultaneously activates three distinct metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG), delivering unprecedented synergistic effects on body weight reduction, glycemic control, and metabolic health.
Retatrutide is a 39-amino-acid linear peptide engineered from the native oxyntomodulin sequence with strategic amino acid substitutions to optimize receptor binding profiles. The peptide is conjugated to a C20 fatty diacid moiety via a gamma-Glu-AEEA-Lys linker at Lys20, enabling strong albumin binding and an extended half-life of approximately 6 days, which supports once-weekly subcutaneous administration. Clinical trials have demonstrated record-breaking efficacy: Phase 2 trials showed up to 24.2% mean weight reduction at 48 weeks, while Phase 3 TRIUMPH-4 trial demonstrated 28.7% weight loss (71.2 lbs) at 68 weeks in participants with obesity and knee osteoarthritis.
Shenzhen Zhaoke Biotechnology Co., Ltd. provides high-purity Retatrutide API (CAS No.: 2381089-83-2) with comprehensive analytical documentation for global pharmaceutical developers and research institutions.
Key Selling Points: Triple Receptor Agonism-Simultaneously activates GIP, GLP-1, and glucagon receptors, delivering synergistic metabolic benefits that surpass single- or dual-agonist therapies. The unique triple mechanism enables superior weight loss and glycemic control.
Breakthrough Weight Loss Efficacy-Phase 2: 24.2% weight loss at 48 weeks; Phase 3 TRIUMPH-4: 28.7% (71.2 lbs) at 68 weeks. Over 90% of participants achieved ≥10% weight loss at 12 mg dose. The weight loss curve had not plateaued at trial end.
Osteoarthritis Pain Relief-Phase 3 TRIUMPH-4 demonstrated 75.8% reduction in WOMAC pain scores. Over 12% of treated participants became completely free of knee pain, significantly outperforming semaglutide (42% pain reduction).
Once-Weekly Dosing-C20 fatty diacid conjugation enables albumin binding with a ~6-day half-life, supporting convenient once-weekly subcutaneous injection for improved patient adherence.
Superior Metabolic Profile-Reduces A1C by up to 2.0%, lowers non-HDL cholesterol and triglycerides, and decreases systolic blood pressure. Total fat mass reduced by 26.1% with comparable lean mass preservation.
Well-Tolerated Safety-Side effect profile consistent with GLP-1/GIP receptor agonists. Gastrointestinal events (nausea, diarrhea, vomiting) are the most common and typically transient. No new safety signals identified.

Name: Shenzhen Zhaoke Biotechnology Co., Ltd.

Chemsrc Level: Unverified

Product #: 18

Tel: 0086-19842673490

Address: Room A207-208, Building A, No.3 Branch Park, Leibo Zhongcheng Life Science Park, Pingshan District, Shenzhen, Guangdong, China, 518118

Area: China(Mainland)

Contact: Jade Cheung

Contact Phone #: 19842673490

Email: jade.cheung@zhaokebio.com

Website: http://www.zhaokebio.com

Major Market: North America, Western Europe, Midde East, South Asia

Annual Trade Volume: 10,000,000

Foreign Trade % of Salers: 100%

Major partners:

Detail introduction:
Shenzhen Zhaoke Biotechnology Co., Ltd. operates as a specialized global procurement and supply chain solutions provider focused exclusively on high-quality peptide APIs. Rather than manufacturing, our core competency lies in strategically sourcing, rigorously vetting, and reliably delivering premium peptide products from qualified suppliers across the global pharmaceutical landscape.
We serve as the critical link between world-class peptide producers and pharmaceutical R&D enters, research institutions, and manufacturing enterprises across North America, Europe, Asia Pacific, and emerging markets. Our mission is to eliminate procurement complexity, mitigate supply risk, and ensure uncompromising quality at every stage of the sourcing journey.

Name: Shanghai Nianxing Industrial Co., Ltd

Area: China

Price:
$432.12/10mg $6847.04/1g

Contact: Yang

Product Detail: Retatrutide

Get all suppliers by the below link:

LY3437943 suppliers

2024-07-15 Retatrutide

2024-05-30 LY3437943

2024-09-14 Retatrutide weight-loss peptide

2023-08-03 LY3437943

2023-11-15 Retatrutide